8-K: Achieve Life Sciences Appoints New CFO

Achieve Life Sciences, Inc. announced the appointment of Benjamin Halladay as its new Chief Financial Officer, effective October 5, 2026, and the departure of Mark Oki.

Summary

• Achieve Life Sciences, Inc. has appointed Benjamin Halladay as its new Chief Financial Officer (CFO) and principal financial officer, effective October 5, 2026.
• Mr. Halladay, 40, brings experience from Esperion Therapeutics, Inc., where he served as CFO from November 2022 to September 2026, and prior roles in finance and financial planning.
• He also has experience at NOV Inc. as a Global Finance Manager.
• Mr. Halladay's compensation package includes an annual base salary of $525,000, a discretionary bonus of up to 40%, an option to purchase 200,000 shares, and 200,000 restricted stock units.
• Mark Oki stepped down as CFO effective October 5, 2026, with his separation not attributed to any disagreements regarding financial statements or disclosures.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, primarily due to the appointment of an experienced CFO, though the departure of the previous CFO without stated disagreement is noted.

Positives

• Appointment of Benjamin Halladay, an experienced CFO with a background at Esperion Therapeutics, Inc., to lead financial operations.
• Mr. Halladay's compensation package includes significant equity awards (200,000 stock options and 200,000 RSUs) which align his interests with shareholders.
• The severance package for Mr. Halladay includes provisions for termination without cause or resignation for good reason, offering some security.

Negatives

• Departure of the previous CFO, Mark Oki, although stated to be without disagreement, represents a change in key financial leadership.
• The employment agreement details for Mr. Halladay, including base salary and bonus potential, are substantial.

Risks

• Integration of a new CFO and potential learning curve associated with a new company and its specific financial landscape.
• The terms of Mr. Halladay's severance agreement, particularly in the event of a change in control, could represent a future financial obligation for the company.

Future Outlook

The filing does not contain specific forward-looking financial guidance. The primary forward-looking elements relate to the vesting schedules of the new CFO's equity awards and the conditions for severance payments.

Management Comments

• Benjamin Halladay brings extensive financial experience from his tenure at Esperion Therapeutics, Inc., including serving as Chief Financial Officer.
• Mark Oki's separation as Chief Financial Officer is not a result of any disagreement regarding the Company's financial statements or disclosures.

Industry Context

StockSavvy.ai notes that executive transitions, particularly for key financial roles like CFO, are common in the life sciences sector, often driven by strategic shifts, growth phases, or the need for specialized financial expertise. The compensation package for Mr. Halladay appears competitive within the industry for a company of this size and stage.

Comparison to Industry Standards

• The base salary of $525,000 for a CFO is within the typical range for mid-cap biotechnology or pharmaceutical companies, though it can vary significantly based on company size, stage of development, and geographic location.
• Equity grants (200,000 options and 200,000 RSUs) are substantial and common for incentivizing executives in the sector, aiming to align compensation with long-term shareholder value creation. Specific comparisons would require detailed analysis of peer companies' executive compensation disclosures.
• Severance packages, particularly those triggered by a change in control, are standard practice to retain executives during periods of uncertainty or potential acquisition. The 12-month payout in a change-in-control scenario is a common provision.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of a new CFO with equity incentives may be viewed positively, aligning management with shareholder interests. The departure of the previous CFO is a standard management change.
• Employees: The transition in financial leadership may lead to adjustments in financial reporting processes or priorities.
• Creditors: No immediate impact is indicated, as the filing focuses on executive appointments.

Next Steps

• Benjamin Halladay will assume the role of Chief Financial Officer on October 5, 2026.
• The full text of Mr. Halladay's Employment Agreements will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2026.

Key Dates

Recommendation

The filing reports a standard executive appointment and departure, which is a routine event and does not provide new material financial information or strategic direction that would warrant a change in investment recommendation. The appointment of an experienced CFO is a positive, but it is an expected event in the normal course of business.

Keywords

Chief Financial Officer, CFO Appointment, Executive Appointment, Management Change, Severance Agreement, Stock Options, Restricted Stock Units, Esperion Therapeutics